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IMMUNOGENIC POTENTIAL OF MEDIUM-DOSE INTERMITTENT 
CYCLOPHOSPHAMIDE THERAPY IN MURINE TRIPLE-NEGATIVE BREAST 
CANCER TUMOR LINES 4T1 AND E0771 
CAMERON VERGATO 
ABSTRACT 
Triple-negative breast cancer (TNBC) is characterized by poor prognosis, 
increased tumor aggression and typically occurs in younger women. 
Chemotherapy drugs are currently used to treat TNBC, however research into 
novel therapies is essential to improve patient outcomes. Immunogenic 
chemotherapy uses cytotoxic drugs to induce an immune stimulatory form of cell 
death, known as immunogenic cell death (ICD). ICD stimulates innate and 
adaptive immune responses to the tumor and can result in tumor ablation and 
anti-tumor immunity. Production of type-1 interferons has sometimes been 
associated with ICD, and these cytokines and their downstream genes are 
known to be involved in immune cell attraction and activation. Here we 
investigate the immunogenic potential of two TNBC cell lines, E0771 and 4T1, 
using cyclophosphamide, an established ICD-inducing chemotherapeutic drug. 
Strong induction of type-1 IFN signaling to downstream genes was induced in 
both cell lines by treatment with the chemically activated cyclophosphamide 
derivative, 4-hydroperoxycyclophosphamide (4HC). Antibody treatment against 
IFNα/β receptor 1 partially blocked some of these 4HC-induced gene responses, 
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which suggested that 4HC activates additional pathways to induce IFN-
stimulated genes. Additionally, 4HC-treated cells secreted soluble factors 
capable of inducing these genes in drug-free cells. 4T1 and E0771 tumors 
implanted orthotopically into syngeneic mice were treated with 
cyclophosphamide on a 6-day medium-dose intermittent schedule. Tumor 
responses were distinct between cell lines. Type-1 IFN gene responses were 
induced by cyclophosphamide in 4T1 tumors, but the responses were weak in 
E0771 tumors. Nevertheless, E0771 tumors rapidly regressed after two cycles of 
cyclophosphamide treatment with strong tumor infiltration by cytotoxic T-cells, 
natural killer cells, macrophages and dendritic cells. In contrast, 4T1 tumors 
entered growth stasis after two treatment cycles that lasted through 7 cycles, with 
weaker immune cell infiltration that lacked natural killer cells. IFN-stimulated 
gene induction in E0771 tumors peaked 3 days after the first cyclophosphamide 
treatment and was followed by immune cell infiltration starting 3 days later. 
Additionally, in E0771 tumors, expression of Foxp3, an immunosuppressive 
regulatory T-cell biomarker, decreased by 70% within 3 days of 
cyclophosphamide treatment. Thus, cyclophosphamide given on a metronomic 
schedule may be efficacious for treating some TNBC tumors, with striking 
differences between tumor models in the activation of type-1 IFN signaling, 
immune cell recruitment and tumor regression responses.   
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Introduction 
Breast cancer is one of the most common causes of cancer-related deaths in 
women in the United States (Siegel et al., 2017). 15-20% of these cancers are 
known as triple-negative breast cancers (TNBC) and are characterized by 
increased tumor aggression and poorer prognosis than other subtypes (Mara et 
al., 2019). TNBC is distinct from other breast carcinomas due to the lack of 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) gene expression (Hudis and Giana, 2011). 
Consequently, treatment options for patients diagnosed with TNBC are limited, 
and thus, research into novel therapies is critically important. 
Immunogenic chemotherapy may represent a potential treatment option for 
TNBC. Certain anti-cancer drugs can induce immunogenic cell death (ICD), 
which is a unique type of cell death capable of vaccinating against cancer (Kepp 
et al., 2014) through stimulation of the innate and adaptive immune systems 
(Garg et al., 2015).  Chemotherapy-induced ICD is characterized by certain 
damage associated molecular patterns (DAMPs), including translocation of the 
pro-phagocytic signal, calreticulin, to the cell surface (Chao et al., 2010), release 
of the toll-like receptor 4 (TLR4) ligand, high-mobility group box 1 protein 
(HMGB1) (Zitvogel et al., 2008), production of type-1 interferons (IFNs) (Sistigu 
et al., 2014),  and extracellular ATP release (Elliot et al., 2009). Dendritic cells 
are attracted by DAMPs released by tumor cells undergoing ICD, engulf the dead 
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and dying tumor cells and are subsequently stimulated into maturation (Garg et 
al., 2017). Mature dendritic cells produce immunostimulatory cytokines that 
recruit CD8+ T-cells, CD4+ T-cells, and natural killer cells to the tumor, which 
eventually lead to tumor regression and activation of tumor-specific immunity 
(Garg et al., 2017). Cytotoxic drugs approved for use in breast cancer that are 
known to induce ICD include doxorubicin (Cesares et al., 2005), 
cyclophosphamide (CPA) (Schiavoni et al., 2011), epirubicin (Sun et al., 2016), 
and mitoxantrone (Garg et al., 2017). This thesis investigates two of these drugs, 
CPA and doxorubicin, for immune stimulatory potential in two murine TNBC cell 
line models.  
In previous studies, the Waxman laboratory used CPA, a commonly used cancer 
chemotherapeutic alkylating agent, to induce ICD in the GL261 murine glioma 
tumor model (Wu and Waxman, 2014). These studies optimized the ICD inducing 
potential of CPA by administering it on a metronomic schedule to mice implanted 
with GL261 tumors. This medium-dose intermittent chemotherapy (MEDIC) 
schedule of CPA treatment (Wu and Waxman, 2018) caused complete tumor 
elimination and activates long-term anti-tumor immunity in GL261 gliomas 
implanted in syngeneic immune competent mice (Wu and Waxman, 2015). Thus, 
our lab’s prior experience and success with CPA given on a MEDIC schedule 
makes it an ideal choice for testing on TNBC.  
3 
 
 
 
 
Further studies in the GL261 model showed that CPA given on a MEDIC 
schedule activates type-1 IFN signaling in GL261 tumors, and chemically 
activated CPA derivative, 4-hydroperoxycyclophosphamide (4HC), also induces 
an IFN response in cultured GL261 cells (Dr. Bin Du, Unpublished Data). This 
IFN response is consistent with one of the aforementioned patterns associated 
with ICD and suggests that type-1 IFN production may serve as a biomarker for 
immunogenic potential of cancer cells. Therefore, we set out to investigate CPA-
induced type-1 IFN responses in TNBC cell lines. 
Type-1 IFNs, IFNα and IFNβ, are cytokines that are secreted in response to viral 
or bacterial infection, where the microbial gene products and bacterial cell wall 
components are detected by toll-like receptors (TLRs) or cytosolic sensors of 
specific nucleic acids (Cheon et al., 2014). Once produced, the IFNs bind to the 
heterodimeric IFN α/β receptor (IFNAR) and modify downstream expression of 
interferon-stimulated-genes (ISGs), which produce proteins with 
immunomodulatory effects such as immune cell recruitment, type-2 IFN 
production and immune cell activation (Cheon et al., 2014).  In cancer, type-1 
IFN signaling is involved in immunosurveillance to help against spontaneous 
tumor formation and is critical to the efficacy of some cancer therapies in mouse 
models including antibodies against HER2, anthracyclines, checkpoint inhibitors, 
and lenalidomide (Zitvogel et al., 2015).  
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One of the mammary carcinoma models we have chosen to study is 4T1. This 
murine TNBC cell line was derived from a spontaneously formed mammary 
tumor in a Balb/c mouse, and it is representative of metastatic late-stage breast 
cancer (Tao et al., 2008). The 4T1 model undergoes ICD in tumors formed from 
4T1 cells engineered to overexpress calreticulin (Wang et al., 2017). Thus, 4T1 
tumors may have the immunogenic potential to respond positively to CPA given 
on a MEDIC schedule.  
The second breast cancer model we investigate is E0771, which is derived from 
a medullary breast adenocarcinoma that formed spontaneously in C57BL/6 mice 
(Ewens et al., 2005). Unlike 4T1, the E0771 TNBC cell line models spontaneous 
breast cancer (Huang et al., 2015). In a study where orthotopic E0771 tumors 
were treated with doxorubicin combined with inflammatory cytokine, interleukin-2, 
tumor regression with specific anti-tumor immunity was achieved (Ewens et al., 
2006). Furthermore, CD8+ T-cells were shown to be a critical player in the 
response (Ewens et al.,2006).  Since the immunogenic potential of the E0771 
tumors was demonstrated in that study, we investigated the effectiveness of CPA 
with a MEDIC schedule on this TNBC model. Additionally, we included 
doxorubicin in our study as a possible alternative to CPA.  
In this study, we explore the immunogenic potential of CPA and doxorubicin in 
4T1 and E0771 TNBC tumor models and investigate the mechanism of the type-
1 IFN response associated with immune cell stimulation. We first assay 
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interferon-stimulated-genes (ISGs) in response to 4HC or doxorubicin in vitro. 
Additionally, murine melanoma B16F10 cells are included in the study as a 
negative control, since they are unresponsive to metronomic CPA in vivo (Wu et 
al., 2016). For the responsive cell lines, we assess the dependence on the 
IFNα/β receptor-1 (IFNAR-1) pathway. Next, we implant the responsive cell lines 
in immune-competent mice syngeneic to the tumor line. These mice are treated 
with CPA on a MEDIC schedule for multiple cycles and monitored for changes in 
tumor growth. At the end of treatment, tumors are assessed for immune cell 
infiltration and ISG induction based on qPCR using marker genes to identify any 
immunogenic activity.  
Our findings demonstrate that both 4T1 and E0771 models generate a type-1 
IFN response to 4HC in vitro. Both cell lines are confirmed to be at least partially 
reliant on the IFNAR-1 pathway for IFN signaling. However, our in vivo studies 
show a dramatic difference between the models’ responsiveness to CPA 
administered on a MEDIC schedule. 4T1 tumors remained static throughout the 
treatment, but E0771 tumors regressed strongly. Additionally, E0771 tumors 
showed strong immune recruitment with this regression, but 4T1 tumors did not. 
Conversely, 4T1 tumors showed stronger type-1 IFN signaling than E0771 
tumors, which will warrant further study of the pathway’s role in the E0771 model. 
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Materials and Methods 
Tumor cell lines - Murine triple-negative breast cancer cell lines E0771 and 4T1 
were purchased from CH3 BioSystems (Amherst, NY) and American Type 
Culture Collection (ATCC) (Manassas, VA), respectively. Murine melanoma cell 
line B16F10 was purchased from ATCC. E0771 and 4T1 cells were cultured in 
RPMI-1640 medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Thermo Fisher 
Scientific) at 37°C under a humidified 5% CO2 atmosphere. B16F10 cells were 
cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS and 
1% penicillin-streptomycin under the same conditions. For culture experiments, 
cells were counted using a Countess Automated Cell Counter (Thermo Fisher) 
according to the manufacturer’s instructions.  
MTS Assay – Cells were seeded in 96-well plates, at 3,000 cells per well, 1 day 
prior to treatment and then exposed to 10-9-10-4M chemically activated 
cyclophosphamide derivative, 4-hydroperoxycyclophosphamide (4HC) (Cat # 
19527 Cayman Chemical, Ann Arbor, MI)  or doxorubicin (Cat #D1515 Sigma-
Aldrich, St. Louis, MO) for 4 hours. After treatment, cells were washed once with 
PBS, and media was replaced with drug-free media. 68 hours later, 10 µl of MTS 
reagent (Cat # G5421, Promega, Madison, WI) was added to assay cell viability, 
and the cells were incubated at 37°C. Absorbance at 490 nm was measured 
every 30 minutes using a BioTek (Winooski, VT) Synergy H1 plate reader, and 
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the time-point where untreated cells reached A490= 1.0 was used for IC50 
calculations. IC50 values were determined using non-linear curve fitting 
implemented in Prism VIII to generate dose-response viability curves.  
In vitro drug treatment - Cells were treated with 4HC or doxorubicin. Cells were 
treated for 4 hours in 6-well plates seeded, at 50,000 cells per well for E0771 
cells and 75000 cells per well for 4T1 and B16F10 cells, on the previous day at 
IC50 concentrations determined by MTS Assay. After treatment, cells were 
washed once with PBS followed by replacement of fresh media. The cells were 
harvested 24, 48 and 72 hours after the start of drug treatment, as indicated, 
followed by downstream RNA isolation.  
Quantitative Polymerase Chain Reaction (qPCR) Sample Preparation - Tumor 
samples excised from mice were homogenized in 1 mL of TRIzolTM Reagent (Cat 
# 15596018, Invitrogen, Carlsbad, CA). Cultured cells from in vitro experiments 
were lysed 1 mL TRIzolTM per well of a 6-well plate. Total RNA from all samples 
was isolated via TRIzolTM-chloroform organic extraction and precipitated with 
isopropanol. After an ethanol wash, RNA pellets were resuspended in 20-1000 
µL of ultrapure water depending on the pellet size and were quantified using a 
BioTek Synergy H1 plate reader. 1 µg of total RNA was treated with RNase-free 
RQ1 DNase (Cat # M6101, Promega) according to the manufacturer’s 
instructions followed by cDNA synthesis using a High-Capacity cDNA Reverse 
Transcription kit (Cat # 466814, Applied Biosystems, Foster City, CA). 
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qPCR - qPCR was performed on cDNA samples using Power SYBRTM Green 
PCR Master Mix (Cat # 4367659, Applied Biosystems) and gene specific primers 
(Table 1) with the CFX384 TouchTM Real-Time PCR Detection System (Biorad, 
Hercules, CA).  Data was analyzed using the comparative Ct method, and gene 
expression, normalized to 18s RNA content, was presented relative to untreated 
cells for in vitro samples and placebo group for in vivo samples. ISGs studied 
include mouse Mx1, Cxcl10, Oasl1, Cxcl11, Igtp, and RSAD2, and immune 
markers studied are mouse CD8α, Nkp46, CD68, IFNG, Prf-1, GZMB, CD11b 
and Foxp3. Target gene primers pairs were designed to span 2 exons, be 18-22 
bp long with close to 50% G:C content and form amplicons 50-150 bp long. 
Unique primer specificity was obtained by extending the primer sequence by 3, 5, 
10, 15 and 20 nucleotides according to the target sequence and using the 
BLAST-like alignment tool (BLAT) in the UCSC Genome Browser to ensure a 
single correct target. Data for culture experiments is presented as mean +/- 
standard deviation (SD) with n = 2-3 replicate samples, and mouse experiments 
are presented as mean +/- standard error of the mean (SEM) with n = number of 
tumors specified.  
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In vitro interferon-β (IFNβ) treatment – At 200,000 cells per well, cells were 
seeded in 6-well plates, incubated overnight, and treated with 28, 83 or 250 U/mL 
recombinant mouse IFNβ1 (Cat # 581302, BioLegend, San Diego, CA) for 4 
hours. Cells were then washed with PBS followed by fresh media replacement. 
Cells were harvested 2 hours later for RNA isolation. 
In vitro polyinosinic-polycytidylic acid (poly (I:C)) transfection – Cells were 
transfected with 1 µg/mL poly (I:C) (Cat # tlrl-picw, Invivogen, San Diego, CA) in 
using 6 µg/mL polyethylenimine (PEI). Cells were seeded in 6-well plates at 
50,000 cells per well for E0771 cells and 75,000 cells per well for 4T1 and 
B16F10 cells. The next day, per well, 2 µL of 1 mg/mL poly (I:C) was mixed with 
12 µL of 1 mg/mL polyethylenimine and 100 µL of serum-free media and 
incubated at room temperature for 15 minutes. This solution was added to 1.886 
mL of full media and placed into 1 well of a 6-well plate for 4 hours.  After 
treatment, cells were washed with PBS followed by addition of fresh media. Cells 
were harvested after 20 hours later for RNA isolation.  
In vitro interferon receptor antibody treatment - Cells were treated with 10 µg/mL 
monoclonal anti-mouse IFNα/β receptor subunit 1 (IFNAR-1) antibody (clone 
MAR1-5A3, Bio X Cell, West Lebanon, NH), which was added to the cells 
together with 4HC, doxorubicin, IFNβ or poly (I:C),  as described above. After 
cells were washed to remove 4HC, doxorubicin, IFNβ or poly (I:C), the cell 
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culture media was replaced with media containing 10 µg/mL IFNAR-1 antibody 
and incubated until cells were collected for RNA isolation.  
Conditioned media treatment - 4T1 and E0771 cells were treated with 4HC at 5 
and 4.2 µM, respectively, and harvested 72 hours after initiating treatment as 
described above. Conditioned media from these “donor” cells was collected, 
transferred to drug-free (naïve) recipient cells in 6-well plates and incubated for 4 
hours. Recipient cells were harvested 2 hours later for RNA isolation. 
Mouse tumor studies - 6-week-old female BALB/c mice (Taconic Farms, 
Germantown, NY) and C57/BL6N mice (Taconic Farms) were housed and 
treated using protocols approved by the Boston University Institutional Animal 
Care and Use Committee. 1 x 105 4T1 cells and 2 x 105 E0771 cells 
resuspended in PBS were inoculated into the fourth mammary fat pad of BALB/c 
and C57/BL6N mice, respectively, using a 5/8-inch-long 26-gauge needle 
(Cat#305115, BD Biosciences, San Jose, CA). Tumor length and width were 
monitored every 3 days post-inoculation via vernier caliper, and tumor volumes 
were calculated using the formula Volume = (π/6) * (L * W )3/2. At tumor volumes 
of 100-150 mm3 for 4T1 tumors and 200-250 mm3 for E0771 tumors, mice were 
randomized into treatment and placebo groups. CPA (Cat # C0768, Sigma-
Aldrich, St. Louis, MO) dissolved in sterile PBS at 15 mg/mL and filtered through 
a 0.2 µm filter was injected intraperitoneally with a 5/8-inch-long 26-gauge needle 
every 6 days at 140 mg/kg. Tumor volumes were measured every 3 days as 
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mentioned above. Mice were euthanized at specified time-points, and their 
tumors were harvested and flash frozen in liquid nitrogen. 
Results 
4T1, E0771 and B16F10 tumor cells are intrinsically sensitive to 4HC and 
doxorubicin - MTS assays were performed to determine the relative sensitivities 
of three tumor cell lines to two cytotoxic drugs, 4HC and doxorubicin, both known 
to stimulate ICD (Pol et al., 2015). MTS viability assays were performed 72 hours 
after initiating 4-hour drug exposure for each cell line in collaboration with Dr. 
Kshama Doshi of this laboratory. IC50 values for 4HC and doxorubicin were 
obtained by plotting relative cell numbers after exposure to a range of drug 
concentrations. IC50 values for 4HC were 6.7 µM (Figure 1A), 3.9 µM (Figure 1B) 
and 19 µM (Figure 1C) for 4T1, E0771 and B16F10 cells, respectively. 
Corresponding IC50 values for doxorubicin cell lines were: 2.7 µM, 1.7µM and 
6.6µM. (Figure 1A-C).  
4HC induces a type-1 IFN response in 4T1 and E0771 cells but not B16F10 cells 
- To investigate cellular IFN responses to 4HC, 4T1 cells were treated with 5 µM 
4HC for 4 hours, and total cellular RNA was extracted and assayed for induction 
of ISGs by qPCR. Mx1 showed no induction at 24 hours but was strongly 
induced after 48-72 hours (Figure 2A). Cxcl10 and Igtp displayed ≥10-fold 
induction after 48 and 72 hours (Figure 2A). These data suggest that 4HC 
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stimulates an IFN response in 4T1 cells, with the strongest response occurring 
after 48-72 hours. In E0771 cells, 4HC (4.2 µM) strongly induced those genes at 
the same time-points seen in 4T1 cells (Figure 2B). By contrast, in B16F10 cells, 
Mx1, Cxcl10 and Igtp induction was minimal compared to other two cell lines with 
≤4-fold induction of each gene (Figure 2C). These findings are consistent with 
the unresponsiveness of B16F10 tumor implants to CPA treatment in C57BL/6 
mice (Wu et al., 2016).  
Doxorubicin induces a strong type-1 interferon response in E0771 cells, but not 
in 4T1 or B16F10 cells - Doxorubicin is another well-studied chemotherapeutic 
drug with immune stimulatory potential, including the ability to induce ICD (Pol et 
al., 2015). All three cell lines were treated with doxorubicin for 4 hours, and RNA 
was extracted and assayed in experiments performed jointly with Dr. Kshama 
Doshi. 4T1 cells treated with 2 µM doxorubicin displayed 5-fold and 10-fold 
induction of Mx1 after 48 and 72 hours, respectively. Cxcl10 and Igtp were 
induced less than 10-fold at any time-point (Figure 3A). Unlike 4HC, doxorubicin 
did not generate a strong IFN response in 4T1 cells. In contrast, doxorubicin-
treated E0771 cells showed strong induction of all three genes, with the strongest 
response occurring after 48 hours (Figure 3B). Thus, doxorubicin induced a 
strong IFN response in E0771 cells. Doxorubicin did not induce a strong ISG 
response in B16F10 cells with Mx1 and Cxcl10 being unresponsive and Igtp 
showing a 2.5-fold induction after 24 and 72 hours and 3.5-fold after 48 hours 
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(Figure 3C). Since doxorubicin only produced a strong response in E0771 cells, 
4HC was used in further experiments on the breast cancer lines.  
Exogenous IFNβ induces ISGs in 4T1 and E0771 cells - We hypothesized that 
the induction of ISGs by 4HC reflects the activity of type-1 IFN signaling. To test 
this hypothesis, we used an inhibitory antibody to IFNAR-1 to ascertain whether 
the ISG responses seen above are downstream of type-1 IFN signaling from this 
receptor. The efficacy of this antibody was first measured by examining its 
inhibitory effects on IFNβ-induced gene responses. 4T1 and E0771 cells were 
treated with increasing doses of IFNβ, with or without IFNAR-1 antibody, for 4 
hours and analyzed for ISG induction 2 hours later. Both cell lines showed very 
strong induction of Oasl1, Cxcl10, and Igtp even at the lowest IFNβ concentration 
tested (28 U/mL of culture medium) (Figure 4A). IFNAR-1 antibody inhibited this 
response by ≥95% at the lowest IFNβ concentration in both cell lines (Figure 4B), 
confirming its inhibitory effectiveness.  
IFNAR-1 antibody partially inhibits ISG induction by 4HC in 4T1 and E0771 cells 
– Since IFNAR-1 antibody blocked direct type-1 IFN pathway stimulation, I used 
this antibody to determine the dependence of 4HC-induced ISG induction on the 
IFNAR-1 pathway. 4T1 and E0771 cells were treated with 4HC, with or without 
IFNAR-1 antibody, for 4 hours and evaluated for ISG induction 68 hours later 
(Figure 5A). In 4T1 cells, Dr. Doshi found that the antibody inhibited the induction 
of Oasl1, Cxcl10 and Igtp by 64, 59 and 96%, respectively (Figure 5B). E0771 
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cells showed similar responses (Figure 5B).  For both cell lines, 4HC induction of 
Oasl1 and Cxcl10 was only partially inhibited, which suggests that 4HC activates 
additional pathways for ISG induction. 
Poly (I:C) stimulates ISG induction in 4T1 and E0771 cells, but IFNAR-1 antibody 
only partially inhibits responses in E0771 cells – Since we observed 4HC-
induced type-1 IFN signaling in both cell lines, we aimed to investigate the 
response mechanism. The type-1 IFN pathway can be stimulated by dsDNA or 
by dsRNA through specific sensor signaling, stimulator of interferon genes 
(STING) (Ishikawa et al., 2009) and retinoic acid inducible gene I (RIG-I) 
(Yoneyama et al., 2004), respectively. We hypothesize that 4HC uses at least 
one of these pathways to effect a type-1 IFN response. Poly (I:C), a synthetic 
double-stranded RNA analogue that can activate the type-1 IFN response 
(Yoneyama et al., 2004), was used to examine sensitivity of each cell line to 
dsRNA. Poly (I:C) was transfected into 4T1 and E0771 cells using polyethylimine 
for 4 hours, and total RNA was analyzed for ISG expression 20 hours later. 
qPCR analysis showed induction of Oasl1, Cxcl10 and Igtp in both cell lines. 
Thus, both cell lines are intrinsically sensitive to dsRNA (Figure 6A). However, 
poly (I:C) induction of Cxcl10 was weaker in E0771 cells (4.3-fold induction; 
Figure 6A) than it was in E0771 cells directly stimulated with IFNβ (Figure 4A) but 
not following treatment with 4HC (Figure 2B) or doxorubicin (Figure 3B). In 4T1 
cells, antibody to IFNAR-1 substantially inhibited induction of all 3 genes, which 
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indicated that the IFN response to poly (I:C) was largely dependent on signaling 
through IFNAR-1 (Figure 6B). However, 43% of the induction of Cxcl10 was not 
inhibited by IFNAR-1 antibody in E0771 cells, which suggests other signaling 
pathways leading to Cxcl10 induction are stimulated by poly (I:C) in this cell line 
(Figure 6B).  
4HC-treated breast cancer cells secrete cytokines capable of inducing ISGs in 
drug naïve cells – Since 4HC induced a type-1 IFN response at the RNA level, 
we wanted to confirm inflammatory cytokine secretion and assess their ability to 
stimulate additional IFN responses. Donor 4T1 cells, prepared by Dr. Doshi, and 
E0771 cells were treated with 4HC as described in previous experiments and 
confirmed to induce ISGs (Figure 7A). Conditioned media from those cells was 
collected 72 hours after initiating drug treatment and placed on drug-naïve cells 
for 4 hours. Total RNA extracted 2 hours later was assayed by qPCR. Recipient 
4T1 cells showed induction for Oasl1, Cxcl10 and Igtp when compared to 
untreated donor cells (Figure 7B). E0771 recipients also were also induced 
(Figure 7B). In both cell lines, the conditioned media induced ISGs in the 
recipient cells, but the induction was notably weaker than in donor cells directly 
exposed to 4HC. These results indicate that 4HC treatment induces 4T1 and 
E0771 cells to secrete one or more immune stimulatory factors that are capable 
of propagating further responses.  
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Metronomic CPA causes drug-dependent tumor stasis in syngeneic 4T1 tumors- 
Since in vitro experiments confirmed IFN pathway stimulation by 4HC in 4T1 
cells, we wanted to determine if metronomic CPA can stimulate in vivo ISG 
induction, immune cell recruitment and tumor regression in 4T1 tumors as seen 
in metronomic CPA-treated GL261 gliomas studied earlier (Wu and Waxman, 
2014)  In collaboration with Dr. Doshi, 4T1 cells were orthotopically injected into 
6-week-old female BALB/c mice. Mice were treated with CPA on a 6-day 
metronomic schedule after tumor volumes reached at least 100mm3. Placebo 
group tumors increased to 450% of initial treatment volume in 12 days. In 
contrast, CPA-treated tumor volumes ranged from 100-200% of treatment day 0 
volumes after of 2, 4 and 7 cycles of CPA treatment (Figure 8A). This indicates 
CPA induced a tumor growth static response that is reversible upon 
discontinuation of drug treatment. Additionally, when treatment was halted after 4 
CPA cycles, the 4T1 tumors resumed growth 12 days later (Figure 8A). Tumors 
were harvested from mice at various time points, and qPCR analysis was 
performed on total RNA extracted from tumors to assay ISG induction and 
immune cell infiltration. The ISGs, Cxcl10 and Mx1 were upregulated after 2, 4 
and 7 CPA cycles, but expression of these ISGs returned to baseline after 
discontinuation of CPA treatment after 4 cycles (Figure 8B). CD8α, NKp46 and 
CD68, which are immune cell markers for cytotoxic T-cells, natural killer cells and 
macrophages, respectively, were chosen to evaluate tumor immune cell 
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infiltration. CD8α expression peaked with a 6-fold increase after 2 cycles and 
decreased as further CPA cycles continued. CD68 peaked at 3-fold after 4 cycles 
and decreased after 7 cycles (Figure 8C). Nkp46 expression showed no 
significant differences from placebo in any group (Figure 8C). Immune effector 
markers IFNG, Prf-1 and GZMB, which represented IFNγ, perforin and granzyme 
B, respectively, were also analyzed (Figure 8D). Each of these genes showed 
peak induction after 2 cycles that decreased with further cycles. Metronomic CPA 
was able to induce ISGs and allow tumor infiltration by cytotoxic T-cells and 
macrophages after two treatment cycles, but the response progressively 
weakened with additional drug cycles. Overall, metronomic CPA was able to 
induce drug tumor stasis but not regression of 4T1 tumors.   
Metrononomic CPA induces strong tumor regression with immune activation in 
syngeneic E0771 tumors- Since E0771 cells also showed IFN responses to 4HC 
in vitro, I evaluated their immunogenic potential and compared the results to 4T1 
tumors. E0771 cells were orthotopically injected into 6-week-old C57BL/6 mice 
and treated with CPA using the same metronomic schedule once the tumor 
volumes reached ≥ 200 mm3. Tumors began to regress after the first CPA 
treatment cycle and continued to decrease in volume sharply throughout the 
second cycle (Figure 9A). ISG analysis of tumor total RNA showed minimal 
induction, with only 4 (Mx1, Cxcl11, Oasl1, Cxcl10) of 6 genes showing 
significant increases compared to placebo, and only Mx1 exceeded a 2-fold 
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increase (Figure 9B). In addition to the above described immune markers, Foxp3 
and Cd11b were also analyzed to assess regulatory T-cells and dendritic cells, 
respectively. All immune cell markers showed significantly increased expression 
compared to placebo (Figure 9C). The cytotoxic effectors Prf-1 and IFNG also 
displayed similar results (Figure 9C). Unlike in 4T1 tumors, metronomic CPA 
treatment induced strong tumor regression and strong immune cell infiltration in 
E0771 tumors. However, ISG induction was weaker than seen in 4T1 tumors. 
Further investigation will be required to evaluate the role of the IFNβ pathway in 
this response.  
CPA-treated E0771 tumors show early ISG induction and a reduced 
immunosuppressive environment prior to tumor regression – We hypothesized 
that the minimal ISG induction in E0771 tumors seen in Figure 9 resulted from 
the lack of sustained IFN signaling through treatment day 12. To investigate this, 
E0771 tumors were established, treated with CPA, and harvested as described 
above 1, 2, 3, 6 (1 cycle) and 12 (2 cycles) days after initial CPA treatment. As 
seen in3 Figure 9, the CPA-treated tumors showed strong regression on day 6 
through day 12 (Figure 10A). ISG induction was apparent by day 2, peaked at 
day 3 and decreased from day 6 onward (Figure 10B), but maximal induction 
never exceeded a 4-fold increase relative to placebo (Figure 10B). Investigation 
of immune cell infiltration showed significant increases in CD8a, NKp46, CD68 
and CD11b compared to placebo by day 6 that persisted at day 12 (Figure 10C). 
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In contrast, Foxp3 decreased significantly from placebo, starting at day 1, and its 
expression continued to drop until day 6 where it rebounded and increased by 
day 12 (Figure 10C). Cytotoxic effector markers, Prf-1 and IFNG, were also 
significantly increased at day 6 and on day 12 (Figure 10C). These results 
confirmed the tumor regression and immune activation with metronomic CPA 
treatment on E0771 tumors. However, the IFN response was still weak compared 
to 4T1 and GL261 tumors (Unpublished data from Dr. Bin Du), which suggests 
alternative pathways may be activated by CPA.   
Discussion 
Effective treatment of TNBC continues to be a difficult challenge with limited 
therapeutic options and high rates of recurrence (Jia et al., 2017). In this study, 
we used two orthotopic mouse models of TNBC, 4T1 and E0771, to investigate 
the potential of immunogenic chemotherapy. Our findings in cell culture studies 
show that exposure to chemically activated CPA derivative, 4HC, near its IC50 
strongly induced expression of multiple ISGs in both TNBC cell lines. The same 
experiments utilizing doxorubicin showed strong induction in E0771 cells but not 
4T1 cells. Investigation into the mechanism of the 4HC response revealed partial 
dependence on IFNAR-1 to stimulate type-1 IFN signaling, which is a pattern 
sometimes associated with ICD (Sistigu et al., 2014). From this data, we 
conclude that 4T1 and E0771 cells are immunogenically responsive to 4HC. 
Further, we showed that the immunogenic response to 4HC seen in vitro can be 
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recapitulated when CPA is used to treat syngeneic mice implanted with 4T1 and 
E0771 tumors. We found that the MEDIC CPA schedule previously described in 
the GL261 model (Wu and Waxman, 2014) induced tumor stasis in 4T1 tumors 
and induced striking tumor regression in E0771 tumors. 4T1 tumors showed 
type-1 IFN signaling with tumor infiltration of some immune cell types, while 
E0771 tumors presented a more limited IFN response but with robust immune 
infiltration. From these results, we conclude that the MEDIC schedule CPA is 
strikingly effective at treating E0771 tumors but not 4T1 tumors, and that the 4T1 
model may require combination chemo-immuno therapies to induce ICD and 
robust anti-tumor responses (Bezu et al., 2015).  
We established that 4HC stimulates strong type-1 IFN signaling in both 4T1 and 
E0771 cells. Type-1 IFN signaling has been observed in breast cancer cells in 
response to other chemotherapeutic drugs such as, topotecan, etoposide, 
cisplatin, paclitaxel and vinblastine (Wan et al., 2012).  Wan et al. linked this 
signaling to increased cell surface expression of major histocompatibility complex 
class I, which is responsible for antigen presentation to T-cells. Additionally, type-
1 IFNs are known to stimulate T-cells, NK cells, macrophages and dendritic cells, 
and some ISGs are known to recruit lymphocytes, monocytes, and macrophages 
(Cheon et al., 2014) Thus, in vitro induction of ISGs may be indicative of in vivo 
immunogenic potential, and further study and comparison of responsive and 
unresponsive TNBC cell lines will help confirm the importance of IFN signaling.  
21 
 
 
 
 
Our investigation into the mechanism of ISG induction by 4HC in 4T1 and E0771 
cells showed the response mostly originated from the IFNAR-1 pathway 
downstream of IFNβ. IFNβ production can be stimulated by dsRNA, ssRNA, 
dsDNA, and ssDNA (Cheon et al., 2014), and we presume that cell damage from 
4HC generates one of these products. We found that 4T1 and E0771 cells were 
both intrinsically sensitive to stimulation by dsRNA analogue poly (I:C), and the 
response was mostly dependent on the IFNβ pathway. Thus, 4HC treatment may 
increase intracellular levels of dsRNA product that stimulates type-1 IFN 
signaling. In future experiments, we will need to test 4T1 and E0771 sensitivity to 
the other nucleic acids, ssRNA, dsDNA and ssDNA, in order to make 
mechanistic conclusions about 4HC. In addition, since our results also show that 
ISG induction from 4HC also comes from another source, we can investigate 
alternative ISG inducing pathways that can act independently of IFNα/β 
signaling, such as tumor necrosis factor α signaling (Wang et al., 2016) 
Our experiments demonstrated that metronomic CPA was able to induce strong 
regression of E0771 tumors but not 4T1 tumors. It will be important to verify this 
this difference is not due to E0771 tumors having increased susceptibility to the 
cytotoxic effects of CPA but rather, is due to the stronger immune infiltration we 
see in the E0771 model. Further experiments will utilize lower dose 
concentrations of CPA to investigate how much cytotoxic nature of CPA affects 
the tumor response.  
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We have observed that CPA treatment increases tumor infiltration of CD8+ T-
cells, natural killer cells, dendritic cells and macrophages in E0771 tumors. 
Based on these findings, we next need to provide evidence that the observed 
immune infiltration plays a functional role in the robust tumor regression. In order 
to evaluate their function in future experiments, we plan to implant these tumors 
in immune-compromised mice and assess any changes in tumor regression. 
Furthermore, if the immune system is required for tumor regression, then our 
next experiments will utilize cell-specific antibody depletion to identify which 
immune cell populations are required for this response.  
Our findings showed that ISGs were weakly induced 3 days before immune cell 
infiltration and tumor regression in E0771 tumors and were strongly induced 
during the tumor stasis in 4T1 tumors. This contrast makes us question the 
importance of type-1 IFNs in both 4T1 and E0771 tumor responses to CPA. Our 
future experiments may utilize IFNAR-1 antibody to block type-1 IFN signaling in 
order to attempt to reveal the contribution of this pathway by observing changes 
in tumor growth or immune infiltration following CPA treatment in both models. 
From our results, we hypothesize that metronomic CPA induces ICD in the 
E0771 tumor model, which recruits immune cells, including cytotoxic T-cells and 
natural killer cells, to induce tumor ablation and specific anti-tumor immunity. 
Further study will be required to determine if we are observing true ICD and its 
resultant anti-tumor immunity. We can test for other ICD hallmarks after CPA of 
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treatment of E0771 tumors, and we can also administer more treatment cycles to 
completely eradicate tumors and subsequently rechallenge with fresh cells to 
observe effects on take-rate. Additionally, investigating the significance of type-1 
IFNs will also be important for our mechanistic understanding of this model.  
Our results presented a large difference in tumor response to CPA between our 
two TNBC tumor models with tumor stasis in 4T1 and tumor regression in E0771. 
This contrast may be due to intrinsic variance between these two cell lines. Yang 
et al. found distinct molecular differences in orthotopic tumors from these models 
with their transcriptomic analysis placing 4T1 and E0771 into separate 
hierarchical clusters that showed transcriptional differences in proliferation, 
differentiation and angiogenesis, and their exomic analysis showed E0771 
tumors were highly mutated with over 2000 observed single nucleotide mutations 
compared to less than 400 in 4T1 tumors. Another study showed that E0771 and 
4T1 tumors have similar CD4+:CD8+ T-cell infiltration ratios, but 4T1 tumors have 
approximately 10-fold higher infiltration of CD4+ and CD8+ T-cells than E0771 
tumors. (Huang et al., 2015). In both tumor lines, immunosuppressive regulatory 
T-cells (Foxp3+ CD4+) increased as tumors grew, but E0771 tumors displayed an 
early growth period where ≥75% of CD4+ cells were also immunostimulatory 
IFNγ+ (Huang et al., 2015.), which may provide a better environment for CPA 
treatment. In future experiments, we aim to observe transcriptomic differences 
between the models after CPA treatment that may allow us to identify causative 
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factors for the weaker response in 4T1 tumors. Ideally, we would to try to inhibit 
factors we find and incorporate that therapy with MEDIC CPA to elicit a 4T1 
tumor response similar to what we see in the E0771 model. We will start by 
conducting RNAseq on tumor samples from each study and comparing 
differences in expression of known immunosuppressive genes.  
Ultimately, our findings may establish a basis for using MEDIC schedule CPA to 
treat some murine TNBC tumors. We would like to confirm if this dose schedule 
is necessary to achieve the striking results seen in the E0771 model and if a 6-
day MEDIC schedule is superior to other CPA regimens, such as the daily oral 
23.3mg/kg dose and the 3-day 70mg/kg dose tested by Chen et al. in the glioma  
model. Once the schedule is optimized for our current models, we can expand 
our testing into other TNBC cell lines including human cells to determine the 
breadth of its effectiveness in this disease. Regarding human cell line efficacy, 
exomic analysis of E0771 and 4T1 tumors examining the top 30 genes most 
frequently mutated in human breast cancer showed 0/30 and 2/30 mutant genes 
for 4T1 and E0771 tumors, respectively (Yang et al. 2017), and this genetic 
difference may lower our ability to predict success in human models. However, 
there are several clinical trials where CPA is used in combination with other 
drugs to treat TNBC with varying degrees of effectiveness (Montagna et al., 
2018; Lim et al., 2018; Ferreira et al., 2018; Sharma et al., 2018), and there may 
be potential for dose and schedule optimizations in these types of studies. Thus, 
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this study and our future studies may serve as a foundation for clinical treatment 
of TNBC.    
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Appendix 
Table 1: Gene-specific qPCR Primers. Primer sequences, length and GC% for 
all genes tested. 
ON# Gene Direction Sequence (5'-3') 
Amplicon 
Length 
(bp) 
G:C 
Content 
(%) 
6987 
Mx1 
Forward  AGAGCTCTGTGCTGGAAGCAC  93 57 
6988 Reverse GCTTCCTCAATTTCAGCACCA 93 48 
7484 
Oasl1 
Forward  GATGTGCGCGTGCTCAAG 80 61 
7485 Reverse CACGGTGCCATTCCCAAA 80 56 
3373 
Cxcl10 
Forward  ACCATGAACCCAAGTGCTGCC 140 57 
3374 Reverse CTATGGCCCTCATTCTCACTGGCC 140 58 
6955 
Igtp 
Forward  CTGAGCCTGGATTGCAGCTT 81 55 
6956 Reverse TGGGTCTGCTCTAGGCCTTG 81 60 
8065 
RSAD2 
Forward  GCCCAAGTATTCACCCCTGT 133 55 
8066 Reverse AAGACATCCTTCGTGCTGCC 133 55 
7936 
Cxcl11 
Forward  ACGGCTGCGACAAAGTTGAA 95 50 
7937 Reverse GGAGGGCTCACAGTCAGACG  95 65 
4255 
CD8α 
Forward  GAAGATTCTGGGGCAGCATGGCAAAG 81 54 
4256 Reverse TTGGAATCAAAACGATCAA 81 30 
4668 
Nkp46 
Forward  GCAACCCCCTGAAACTGGTA 79 55 
4669 Reverse AAGGTTACCTCAGGCTGTGGATA 79 48 
3427 
CD68 
Forward  GCCCGAGTACAGTCTACCTGG 97 62 
3428 Reverse GCCCGAGTACAGTCTACCTGG 97 45 
4253 
Foxp3 
Forward  GCCTTCAGACGAGACTTGGAA 99 52 
4254 Reverse CTGGCCTAGGGTTGGGCATT 99 60 
4261 
CD11b 
Forward  CCAAGAGAATGCAAAAGGCTTT 74 41 
4262 Reverse GGGGGGCTGCAACAACCACA-3’ 74 65 
3429 
IFNG 
Forward  TCTTCAGCAACAGCAAGGCG 79 55 
3430 Reverse CGCTGGACCTGTGGGTTGTTG 79 62 
3565 
Prf-1 
Forward  GTACAACTTTAATAGCGACACAGTA 80 36 
3566 Reverse AGTCAAGGTGGAGTGGAGGT 80 55 
3561 
GZMB 
Forward  TGTCTCTGGCCTCCAGGACAA 110 57 
3562 Reverse CTCAGGCTGCTGATCCTTGATCGA 110 54 
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Figure 1: 4T1, E0771 and B16F10 Drug Sensitivity
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Figure 1. MTS Cell Viability Assays. Data presented as mean +/- SD with n=3 
wells of a 96-well plate. A. 4T1 cells treated with a 5-log10 range of 4HC 
concentrations showed 50% decrease in viability compared to drug-free control 
cells at 6.7 µM. Doxorubicin treatment over a similar concentration range resulted 
in an IC50 value of 2.7 µM in 4T1 cells. B. E0771 cells treated with a 5-log10 range 
of 4HC or doxorubicin concentrations displayed IC50 values of 3.9 µM or 1.7µM, 
28 
 
 
 
 
respectively. C. B16F10 cells exhibited 50% viability at 19 µM or 6.6 µM after 
exposure to a 5-log10 range of 4HC or doxorubicin, respectively.  
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Figure 2: 4HC-Induced Interferon Response
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Cxcl10 28.4 29.3 24.8 24.5
Igtp 28.0 27.8 24.9 24.0
18s 20.7 21.0 20.9 20.8
Avg. CT#
ISGs Untreated 24h 48h 72h
Mx1 39.3 38.8 33.6 32.7
Cxcl10 29.8 29.5 24.7 24.4
Igtp 30.4 29.6 25.2 24.4
18s 21.2 20.7 21.0 21.4
Avg. CT#
ISGs Untreated 24h 48h 72h
Mx1 38.6 38.8 37.7 36.7
Cxcl10 27.5 27.7 26.4 26.0
Igtp 31.1 32.3 29.9 28.6
18s 18.7 19.2 19.3 18.5
Avg. CT#
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Figure 2. qPCR Analysis of 4HC Treatments. Data presented as mean +/- SD 
with n=2-3 replicates. Average CT numbers for each gene are seen in the tables 
to the right of the graph. A. 4-hour treatment of 4T1 cells with 5µM 4HC induced 
ISGs Mx1, Cxcl10 and Igtp 44 and 68 hours later. Mx1, Cxcl10 and Igtp 
expression increased 9, 21 and 13-fold, respectively, at the 48-hour timepoint 
and 26, 25 and 22-fold, respectively, at the 72-hour timepoint. Data is 
representative of two independent experiments with one performed by Dr. Doshi. 
B. 4-hour 4.2 µM 4HC-treated E0771 cells showed a 40, 30 and 29-fold increase 
in Mx1, Cxcl10 and Igtp, respectively, 44 hours later and a 100, 49 and 63-fold 
increase in the same genes, respectively, 68 hours later. Data is representative 
of two independent experiments. C. B16F10 cells treated with 20 µM 4HC for 4 
hours exhibited a 2-fold increase in Mx1 and Cxcl10 and a 3-fold increase in Igtp 
expression 44 hours later. At the 72-hour timepoint, Mx1, Cxcl10 and Igtp 
expression increased 3, 2 and 4-fold, respectively. Experiment performed by Dr. 
Doshi and analyzed and graphed by me. 
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Figure 3: Doxorubicin-Induced Interferon Response
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Figure 3. qPCR Analysis of Doxorubicin Treatments. Data presented as mean +/- 
SD with n=2-3 replicates Average CT numbers for each gene are seen in the 
tables to the right of the graph.  A. 4-hour treatment of 4T1 cells with 2µM 
doxorubicin induced Mx1, Cxcl10 expression 5-fold and 3-fold, respectively, 44 
hours later, but Igtp expression was unchanged. At the 72-hour timepoint, Mx1, 
Cxcl10 and Igtp were induced 9, 5 and 3-fold, respectively. Data shown was 
obtained from Dr. Doshi’s experiment and analyzed and graphed by me. B. 4-
hour 1.7 µM doxorubicin-treated E0771 cells showed a 172, 126 and 92-fold 
increase in Mx1, Cxcl10 and Igtp, respectively, 44 hours later and a 158, 91 and 
82-fold increase in the same genes, respectively, 68 hours later. Data is 
representative of two independent experiments. C. B16F10 cells treated with 6.6 
µM doxorubicin for 4 hours exhibited a 10 and 12-fold increase in Igtp expression 
44 and 68 hours later, respectively, but Mx1 and Cxcl10 were unresponsive at all 
timepoints.     
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Figure 4: IFNAR-1 Antibody Inhibition of Ectopic IFNβ ISG Induction 
A
B
1: Untreated  5: IFNB (28) + IFNAR-1 Antibody 
2: IFNB (28) 6: IFNB (83) + IFNAR-1 Antibody
3: IFNB (83)  7:IFNB (250) + IFNAR-1 Antibody
4: IFNB (250)
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Figure 4. qPCR Analysis of IFNβ and IFNAR-1 Antibody Treatments. Data 
presented as mean +/- SD with n=3 replicates A. 4T1 and E0771 cells were 
treated with 28, 83 and 250 U/mL of mouse IFNβ for 4 hours, with or without 
10µg/mL IFNAR-1 antibody. ISG induction was assayed 2 hours later. In 4T1 
cells, IFNβ induced the expression of Oasl1, Cxcl10 and Igtp by 17-21, 294-412, 
and 187-289-fold, respectively. In E0771 cells, the corresponding inductions by 
IFNβ were 17-18, 7-10, and 93-102-fold, respectively. Cxcl10 induction in E0771 
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cells was much lower than observed in 4T1 cells. Further, 4HC caused a larger 
induction in E0771 cells (Figure 2B) than IFNβ, which suggests that IFNβ may 
not be the only contributor to 4HC induction of Cxcl10 in E0771 cells. This 
hypothesis is further supported by Figure 5 where IFNAR-1 antibody did not 
completely block the induction by 4HC. B. Percent expression calculated from 
data in Figure 4A using the formula (((𝑥 ± 𝑆𝐷) − (𝑧 ± 𝑆𝐷))/(𝑦 ± 𝑆𝐷) − (𝑧 ± 𝑆𝐷)), 
where x = treatment gene expression, z = basal gene expression and y = gene 
expression at 250 U/mL. In 4T1 cells, 10 µg/mL IFNAR-1 antibody inhibited 
Oasl1 induction from 28, 83 and 250 U/mL IFNβ by 95, 90 and 75%, respectively. 
Cxcl10 induction was inhibited 100% at all concentrations, and Igtp percent 
inhibition was 99, 99 and 94%, respective to 28, 83 and 250 U/ml of IFNβ. In 
E0771 cells, 10 µg/mL IFNAR-1 antibody inhibited Oasl1 induction from 28, 83 
and 250U/mL IFNβ by 99, 91 and 82%, respectively. Cxcl10 induction was 
inhibited by 100, 97 and 96%, respectively, while Igtp induction was blocked by 
100, 95 and 89%, respectively. CT numbers from all inhibited samples ranged 
from 26-28, which indicated remaining gene functionality. 
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Figure 5: IFNAR-1 Antibody Inhibition of 4HC ISG Induction 
A
B
1: Untreated  3: 4HC + IFNAR-1 Antibody 
2: 4HC 
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Figure 5. qPCR Analysis of Combined 4HC and IFNAR-1 Antibody Treatments. . 
Data presented as mean +/- SD with n=2-3 replicates  A. In 4T1 cells, 4-hour 
treatment with 5 µM 4HC, with or without 10 µg/mL IFNAR-1 antibody, induced 
Oasl1, Cxcl10 and Igtp expression by 14, 11 and 12-fold 68 hours later, and the 
same treatment with 4.2 µM 4HC on E0771 cells induced Oasl1, Cxcl10 and Igtp 
by 15, 24 and 17-fold. Differences in E0771 expression of Cxcl10 between Figure 
2B and 5A are due to higher basal expression in this experiment (Figure 2B 
CT=29.8, Figure 5A CT=28.41) IFNAR-1 antibody was able to partially inhibit 
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responses in both cell lines. B. Percent expression calculated from data in Figure 
5A using the formula (((𝑥 ± 𝑆𝐷) − (𝑧 ± 𝑆𝐷))/(𝑦 ± 𝑆𝐷) − (𝑧 ± 𝑆𝐷)), where x = 
treatment gene expression, z = basal gene expression and y = gene expression 
with 4HC treatment. In 4T1 cells, IFNAR-1 antibody blocked 4HC induction of 
Oasl1, Cxcl10 and Igtp by 64, 59 and 96%, respectively. The percent inhibition in 
4HC-treated E0771 cells was 65, 53 and 100% for Oasl1, Cxcl10 and Igtp, 
respectively. CT numbers from all inhibited samples ranged from 25-30, which 
indicated remaining gene functionality. 4T1 data shown is representative of 3 
independent experiments performed by Dr. Doshi and analyzed and graphed by 
me. E0771 data show is representative of 2 independent experiments.  
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Figure 6: IFNAR-1 Antibody Inhibition of Poly (I:C) ISG Induction
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Figure 6. qPCR Analysis of Poly (I:C) and IFNAR-1 Antibody Treatments. . Data 
presented as mean +/- SD with n=3 replicates  A. 4T1 cells treated with 1 µg/mL 
poly (I:C) for 4 hours showed 6, 25 and 26-fold induction of Oasl1, Cxcl10 and 
Igtp, expression respectively. 4-hour poly (I:C) induced Oasl1, Cxcl10 and Igtp 
expression by 10, 4 and 20-fold, respectively. IFNAR-1 antibody partially 
inhibited response in both cell lines. B. Percent expression calculated from data 
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in Figure 6A using the formula (((𝑥 ± 𝑆𝐷) − (𝑧 ± 𝑆𝐷))/(𝑦 ± 𝑆𝐷) − (𝑧 ± 𝑆𝐷)), 
where x = treatment gene expression, z = basal gene expression and y = gene 
expression with Poly I:C. IFNAR-1 antibody completely blocked poly (I:C) 
induced expression of Cxcl10 and Igtp and 94% of Oasl1 in 4T1 cells. In E0771 
cells, the antibody inhibited poly (I:C) induction of Oasl1, Cxcl10 and Igtp 
expression by 87, 57 and 98%, respectively. CT numbers from all inhibited 
samples ranged from 26-30, which indicated remaining gene functionality. 4T1 
data shown is representative of 3 independent experiments.  
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Figure 7: ISG Induction by 4HC Treatment Conditioned Media
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Figure 7. qPCR Analysis of Conditioned Media Treatments. Data presented as 
mean +/- SD with n=2-3 replicates A. In 4T1 cells, 4-hour treatment with 5 µM 
4HC induced Oasl1, Cxcl10 and Igtp expression by 8, 9 and 10-fold 68 hours 
later, and the same treatment with 4.2 µM 4HC on E0771 cells induced Oasl1, 
Cxcl10 and Igtp by 27, 36 and 25-fold. These data confirm results from other, 
similar experiments shown in Figure 2 and Figure 5. B. 4-hour treatment with 
conditioned media from the 4T1 cells featured in Figure 7A induced 2, 2 and 5-
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fold increases of Oasl1, Cxcl10 and Igtp, respectively, 2 hours later in drug-naïve 
4T1 cells. The same treatment with E0771 donor cell conditioned media induced 
Oasl1 and Igtp by 2.7 and 11.9-fold, but Cxcl10 was unresponsive. The data 
shown are representative of 2 independent experiments. 4T1 experiments were 
performed and analyzed by Dr. Doshi and graphed by me.   
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Figure 8: 4T1 Tumor Response to Metronomic CPA
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Figure 8. 4T1 Tumor Growth Curves and qPCR Analysis of CPA Treated 
Tumors. A. Tumor volumes for 4T1 tumors orthotopically implanted in the fourth 
mammary fat pads of BALB/c mice and treated with 140 mg/kg CPA (treatment 
days indicated by arrows along x-axis). Tumors from mice after 2, 4 and 7 cycles 
(Day 12, 24 and 42) of CPA treatment entered tumor stasis and remained at 100 
to 200% of initial treatment volume, but placebo mouse tumors grew rapidly and 
exceeded 400% initial volume by day 12. Tumors from mice where CPA 
treatment was halted after day 18 exhibited stasis and grew to 400% volume by 
day 42. Group mean +/- SEM shown, for N=7 tumors for placebo and 2 cycles, 6 
tumors for 4 cycles, 4 tumors for 3 and 7 cycles, and 2 tumors for no treatment 
after 4 cycles.  B. Induction of Mx1 and Cxcl10 was ≥ 6-fold in 2, 4 and 7 CPA 
cycle tumors, but this induction returned to placebo levels in the group that was 
allowed to grow after 4 cycles. Data presented as Mean +/- SEM, n values are 
the same as previously mentioned. Expression of cytotoxic T-cell marker, CD8α, 
increased 6-fold after 2 CPA cycles, but was not significantly different in other 
groups. Natural killer cell marker, NKp46, expression was not induced in any 
group, and CD68 macrophage marker expression increased 2, 2.6 and 1.5-fold in 
2, 4 and 7 cycle groups, respectively. Expression of immune effector markers 
IFNG, Prf-1 and GZMB increased 6.8, 4.7 and 3.6-fold after 2 cycles, 
respectively, and Prf-1 and GZMB levels remained elevated to 3.7 and 2.7-fold 
after 4 cycles, respectively. Data presented as Mean +/- SEM, and significance 
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was determined by 1-way ANOVA (*=P ≤ 0.05), (**=P ≤ 0.01), (***=P ≤ 0.001), 
(****=P ≤ 0.0001). Data was obtained in collaboration with Dr. Doshi.  
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Figure 9: E0771 Tumor Response to Metronomic CPA 
C
B
A
-3
3
-3
0
-2
7
-2
4
-2
1
-1
8
-1
5
-1
2 -9 -6 -3 0 3 6 9 12 15
0
100
200
300
400
E0771
Days
N
o
rm
a
li
z
e
d
 t
u
m
o
r 
v
o
lu
m
e
 (
%
)
2 cycles
Placebo
MX1 Cxcl11 RSAD2 Igtp Oasl1 Cxcl10
0
1
2
3
E0771
Genes
N
o
rm
a
li
z
e
d
 R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
Placebo
2 cycles
✱✱
✱
✱
✱
CD8a NKp46 CD68 Foxp3 CD11b
0
10
20
30
40
E0771
Genes
N
o
rm
a
li
z
e
d
 R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
Placebo
2 cycles
✱✱
✱✱
✱✱
✱
✱✱✱✱
IFNG Prf-1
0
5
10
15
E0771
Genes
N
o
rm
a
li
z
e
d
 R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
Placebo
2 cycles
✱✱✱
✱✱
Placebo 
2 Cycles
D
 
45 
 
 
 
 
Figure 9. E0771 Tumor Growth Curves and qPCR Analysis of 2 Cycle CPA 
Treated Tumors. A. Tumor volumes for E0771 tumors orthotopically implanted in 
C57BL/6 mice and treated with 140mg/kg CPA (treatment days indicated by 
arrows in the x-axis). Tumors from mice treated with 2 cycles of CPA regressed 
to 50% of initial treatment volume by day 12, but placebo mouse tumors reached 
≥ 300% by day 6. Data presented as mean +/- SEM, with n=7 and n=10 tumors 
for placebo and 2 CPA cycle groups, respectively. B. Induction of Mx1, Cxcl11, 
Oasl1 and Cxcl10 was significant after two CPA cycles but only with 2.3, 1.6, 1.2 
and 1.3-fold inductions, respectively. Data are presented as mean +/- SEM, with 
n values being the same as Figure 9A. C. Expression of immune markers, CD8α, 
NKp46, CD68, Foxp3, CD11b, IFNG and Prf-1 was increased 29.3, 7.8, 3.9, 2.6, 
3.7, 10.1 and 7.3-fold, respectively, after 2 CPA cycles. Data presented as mean 
+/- SEM, with n values being the same as Figure 9A, and significance was 
determined by two-tailed T-test (*=P ≤ 0.05), (**=P ≤ 0.01), (***=P ≤ 0.001), 
(****=P ≤ 0.0001). 
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Figure 10: E0771 Early Response to Metronomic CPA 
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Figure 10. E0771 Tumor Growth Curves and qPCR Analysis of CPA Treated 
Tumors Harvested 1, 2, 3, 6 and 12 Days After Treatment. A. Tumor volume 
curves for E0771 tumors orthotopically implanted in C57BL/6 mice and treated 
with 140 mg/kg CPA (treatment days indicated by arrows along x-axis). CPA-
treated tumors harvested 1, 2 and 3 days after CPA treatment grew similarly to 
placebo. Tumors from the remaining treatment groups that regressed by day 6, 
and the 2 CPA cycle group regressed to 26% of initial treatment volume by day 
12. Data are presented as mean +/- SEM, with n=6 tumors for all groups. B. 
Expression of ISGs Mx1, RSAD2, Igtp, Oasl1 and Cxcl10 increased 2.1, 2.2 1.9, 
2.1, 2.2 and 2.7-fold, respectively, 2 days after treatment and 3.1, 2.4, 2.1, 2.6, 
and 3.2-fold, respectively at day 3 alongside a 3.3-fold Cxcl11 increase. Mx1, 
Cxcl11, Igtp and Cxcl10 induction sustained into day 6 but at lower expression 
levels.  Data presented as mean +/- SEM, with n=6 for all groups. C. Expression 
of immune markers, CD8α, NKp46, CD68, CD11b, IFNG and Prf-1 was 
increased 7.6, 6.5, 2.4, 4.4 and 6.7-fold, respectively, after 1 CPA cycle after 
treatment and 9.9, 6.4, 3.4, 3.2, 4.6 and 7.9-fold, respectively, after 2 CPA 
cycles. Foxp3 expression decreased to 57, 28 and 29% of placebo expression 
after 1, 2 and 3 days after treatment, respectively, before increasing to 2.2-fold 
by day 12.  Data presented as mean +/- SEM, with n=6, and significance was 
determined by two-tailed T-test (*=P ≤ 0.05), (**=P ≤ 0.01), (***=P ≤ 0.001), 
(****=P ≤ 0.0001). 
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